Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors

Grifols Italia S.p.A25 enrolled

Overview

This is an observational, prospective, longitudinal, multicenter, cohort study designed with the scope to verify whether or not TGA may predict effectiveness of different FVIII concentrates class (devoid or rich of VWF) in patient affected by severe or moderately severe inherited haemophilia A and inhibitors.

Rationale: Hemophilia A is a serious and common hereditary bleeding disorder caused by deficiency of coagulation factor VIII (FVIII). Patients with this disease are treated with recombinant factor VIII or factor VIII concentrates derived from plasma. Administration of exogenous FVIII in 15-35% of cases, cause the formation of antibodies to FVIII (inhibitors) that neutralize the activity of factor VIII, making the treatment ineffective.The development of inhibitors of factor VIII (FVIII) is the most serious and challenging complication of the treatment of hemophilia A and represents the highest economic burden for a chronic disease. Therefore, research is making great efforts to optimize the best therapeutic approach for the disease. It has been observed that FVIII inhibitors display a wide range of immunoreactivity when tested against different classes of FVIII concentrates (with/without von Willebrand factor -VWF). It has been demonstrated that the different inhibitors reactivity may correlate with different ability of inhibitors to impair thrombin generation, as tested by Thrombin Generation Assay (TGA). In these patients TGA assay might be a tool to predict which FVIII concentrate has the greater haemostatic effectiveness. It is also uncertain if the different classes of FVIII used in ITI protocols may have a different effectiveness in reducing the occurrence of BT bleedings and if this may correlate to lower reactivity, epitope specificity, VWF content and may be predicted by TGA. It would be very helpful to be able to give an evidence based diagnostic and prognostic instrument, the TGA, to aid physician to optimize the therapy for all inhibitors patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Severe Hemophilia A With Inhibitor

Interventions

TGA (Thrombin generation Assay)OTHER

TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the "most effective". The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of inherited, severe (FVIII:C \< 1%) or moderately severe haemophilia A (FVIII ≤ 2%) * Any age * Ability to comply with study methods and willingness to participate to the study * Written informed consent. FOR THE LOW RESPONDERS COHORT \- Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre \>0.6 and \< 5 BU/ml tested by Bethesda assay, Nijmegen modification). It will be included in this study those patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre \>0.6 and \< 5 BU/ml and no increase in the INH titer \> 5 BU over treatment with FVIII) INCLUSION CRITERIA FOR THE HIGH RESPONDERS COHORT * Documented high response after FVIII exposure (FVIII inhibitors titre \> 5 BU/ml tested by Bethesda assay, Nijmegen modification). It will be included in this study those patients who are potential candidates to a first or rescue ITI. * Any historical peak ≥ 5 BU Exclusion Criteria: * Diagnosis of acquired haemophilia * Diagnosis of inherited mild haemophilia A (FVIII \> 2%) * Life expectancy lower than 1 year * Psychiatric illness and any other conditions may impair ability to comply with study methods

Locations (15)

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

Bari, Apulia, Italy

ACTIVE_NOT_RECRUITING

Outcomes

Primary Outcomes

Thrombin generation result

Thrombin generation results of the TGA applied on plasma patients whith inhibitor matched with different class of FVIII concentrate

Time frame: 12 months

Secondary Outcomes

Epitope mapping results

epitope mapping test on the plasma patient during the therapy for a follow-up period of 12 month

Time frame: 12 months

Incidence of all breakthrough (BT) bleedings

events/month

Time frame: 12 months

Total FVIII dose required to treat the patients

(IU/year)

Time frame: 12 months

the inhibitor titre course

Time frame: 12 months

Use of bypassing agents

incidence of BT bleedings who require bypassing agents (events/months) average dose of bypassing agents (or days of treatment) needed to treat BT bleedings total dose of bypassing agent (and days of treatment) required overall (IU/year) and (days of treatment/year)

Time frame: 12 months

ITI outcome only for patient under this kind of treatment

% of Success (total, partial success or failure will be defined as in ITI study protocol) Time to tolerance (months), defined as the time to ITI success (total/partial)

Time frame: 3 years

Central Contacts

Elena Santagostino, Scientific Coordinator

CONTACT

+39 02 55035273 hemophilia_ctr@policlinico.mi.it

Elisa Mancuso

CONTACT

+39 02 55035273 hemophilia_ctr@policlinico.mi.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.